Is Broadcom Stock Overvalued?
The semiconductor company Broadcom Inc. (NASDAQ:AVGO) is having a stellar…
Sell
50
QGEN Quote, Financials, Valuation and Earnings
Last price:
$44.69
Seasonality move
:
7.3%
Day range:
$44.59 - $45.27
52-week range:
$39.03 - $47.44
Dividend yield:
0%
P/E ratio:
109.88x
P/S ratio:
4.97x
P/B ratio:
2.81x
Volume:
990.7K
Avg. volume:
753.6K
1-year change:
-3.56%
Market cap:
$9.9B
Revenue:
$2B
EPS (TTM):
$0.41
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
QGEN
Qiagen NV
|
$519.1M | $0.60 | 1.95% | 39.42% | $51.14 |
|
HAE
Haemonetics
|
$352.9M | $1.17 | 5.26% | 92.62% | $110.80 |
|
LENZ
LENZ Therapeutics
|
-- | -$0.40 | -- | -57.13% | $39.29 |
|
MRUS
Merus NV
|
$9M | -$0.94 | -4.27% | -10.77% | $86.07 |
|
ORKA
Oruka Therapeutics
|
-- | -$0.98 | -- | -29.53% | $43.17 |
|
QURE
uniQure NV
|
$19M | -$0.53 | 194.09% | -62.87% | $30.59 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
QGEN
Qiagen NV
|
$44.68 | $51.14 | $9.9B | 109.88x | $1.28 | 0% | 4.97x |
|
HAE
Haemonetics
|
$76.67 | $110.80 | $3.9B | 31.81x | $0.00 | 0% | 2.90x |
|
LENZ
LENZ Therapeutics
|
$23.21 | $39.29 | $638.3M | -- | $0.00 | 0% | -- |
|
MRUS
Merus NV
|
$43.85 | $86.07 | $3B | -- | $0.00 | 0% | 75.06x |
|
ORKA
Oruka Therapeutics
|
$15.72 | $43.17 | $550.2M | -- | $0.00 | 0% | -- |
|
QURE
uniQure NV
|
$13.85 | $30.59 | $675.1M | -- | $0.00 | 0% | 23.44x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
QGEN
Qiagen NV
|
35.23% | 0.190 | 18.96% | 1.62x |
|
HAE
Haemonetics
|
58.23% | 0.862 | 30.25% | 1.87x |
|
LENZ
LENZ Therapeutics
|
-- | 3.796 | -- | -- |
|
MRUS
Merus NV
|
-- | 1.670 | -- | 7.94x |
|
ORKA
Oruka Therapeutics
|
-- | 0.000 | -- | -- |
|
QURE
uniQure NV
|
47.8% | -7.855 | 21.27% | 6.18x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
QGEN
Qiagen NV
|
$308.3M | $120.8M | 1.8% | 2.58% | 25.49% | $138M |
|
HAE
Haemonetics
|
$187.4M | $51.7M | 6.54% | 13.51% | 14.96% | $39.4M |
|
LENZ
LENZ Therapeutics
|
-- | -$12.9M | -- | -- | -- | -$10.8M |
|
MRUS
Merus NV
|
-- | -$72.2M | -47.97% | -47.97% | -613.59% | -$80.7M |
|
ORKA
Oruka Therapeutics
|
-- | -$29.4M | -- | -- | -- | -- |
|
QURE
uniQure NV
|
$1.3M | -$40.2M | -96.96% | -154.29% | -1215.48% | -$45.3M |
Qiagen NV vs. Competitors
-
Which has Higher Returns QGEN or HAE?
Haemonetics has a net margin of 19.54% compared to Qiagen NV's net margin of 9.79%. Qiagen NV's return on equity of 2.58% beat Haemonetics's return on equity of 13.51%.
Company Gross Margin Earnings Per Share Invested Capital QGENQiagen NV61.43% $0.44 $5.4B HAEHaemonetics54.25% $0.66 $2.1B -
What do Analysts Say About QGEN or HAE?
Qiagen NV has a consensus price target of $51.14, signalling upside risk potential of 14.47%. On the other hand Haemonetics has an analysts' consensus of $110.80 which suggests that it could grow by 44.52%. Given that Haemonetics has higher upside potential than Qiagen NV, analysts believe Haemonetics is more attractive than Qiagen NV.
Company Buy Ratings Hold Ratings Sell Ratings QGENQiagen NV7 7 0 HAEHaemonetics3 2 0 -
Is QGEN or HAE More Risky?
Qiagen NV has a beta of 0.366, which suggesting that the stock is 63.358% less volatile than S&P 500. In comparison Haemonetics has a beta of 0.410, suggesting its less volatile than the S&P 500 by 59.02%.
-
Which is a Better Dividend Stock QGEN or HAE?
Qiagen NV has a quarterly dividend of $1.28 per share corresponding to a yield of 0%. Haemonetics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Qiagen NV pays -- of its earnings as a dividend. Haemonetics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios QGEN or HAE?
Qiagen NV quarterly revenues are $501.9M, which are larger than Haemonetics quarterly revenues of $345.5M. Qiagen NV's net income of $98.1M is higher than Haemonetics's net income of $33.8M. Notably, Qiagen NV's price-to-earnings ratio is 109.88x while Haemonetics's PE ratio is 31.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Qiagen NV is 4.97x versus 2.90x for Haemonetics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income QGENQiagen NV4.97x 109.88x $501.9M $98.1M HAEHaemonetics2.90x 31.81x $345.5M $33.8M
-
Which has Higher Returns QGEN or LENZ?
LENZ Therapeutics has a net margin of 19.54% compared to Qiagen NV's net margin of --. Qiagen NV's return on equity of 2.58% beat LENZ Therapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital QGENQiagen NV61.43% $0.44 $5.4B LENZLENZ Therapeutics-- -$0.38 -- -
What do Analysts Say About QGEN or LENZ?
Qiagen NV has a consensus price target of $51.14, signalling upside risk potential of 14.47%. On the other hand LENZ Therapeutics has an analysts' consensus of $39.29 which suggests that it could grow by 69.26%. Given that LENZ Therapeutics has higher upside potential than Qiagen NV, analysts believe LENZ Therapeutics is more attractive than Qiagen NV.
Company Buy Ratings Hold Ratings Sell Ratings QGENQiagen NV7 7 0 LENZLENZ Therapeutics4 0 0 -
Is QGEN or LENZ More Risky?
Qiagen NV has a beta of 0.366, which suggesting that the stock is 63.358% less volatile than S&P 500. In comparison LENZ Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock QGEN or LENZ?
Qiagen NV has a quarterly dividend of $1.28 per share corresponding to a yield of 0%. LENZ Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Qiagen NV pays -- of its earnings as a dividend. LENZ Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios QGEN or LENZ?
Qiagen NV quarterly revenues are $501.9M, which are larger than LENZ Therapeutics quarterly revenues of --. Qiagen NV's net income of $98.1M is higher than LENZ Therapeutics's net income of -$10.2M. Notably, Qiagen NV's price-to-earnings ratio is 109.88x while LENZ Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Qiagen NV is 4.97x versus -- for LENZ Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income QGENQiagen NV4.97x 109.88x $501.9M $98.1M LENZLENZ Therapeutics-- -- -- -$10.2M
-
Which has Higher Returns QGEN or MRUS?
Merus NV has a net margin of 19.54% compared to Qiagen NV's net margin of -848.67%. Qiagen NV's return on equity of 2.58% beat Merus NV's return on equity of -47.97%.
Company Gross Margin Earnings Per Share Invested Capital QGENQiagen NV61.43% $0.44 $5.4B MRUSMerus NV-- -$1.46 $703.3M -
What do Analysts Say About QGEN or MRUS?
Qiagen NV has a consensus price target of $51.14, signalling upside risk potential of 14.47%. On the other hand Merus NV has an analysts' consensus of $86.07 which suggests that it could grow by 96.29%. Given that Merus NV has higher upside potential than Qiagen NV, analysts believe Merus NV is more attractive than Qiagen NV.
Company Buy Ratings Hold Ratings Sell Ratings QGENQiagen NV7 7 0 MRUSMerus NV12 0 0 -
Is QGEN or MRUS More Risky?
Qiagen NV has a beta of 0.366, which suggesting that the stock is 63.358% less volatile than S&P 500. In comparison Merus NV has a beta of 1.104, suggesting its more volatile than the S&P 500 by 10.426%.
-
Which is a Better Dividend Stock QGEN or MRUS?
Qiagen NV has a quarterly dividend of $1.28 per share corresponding to a yield of 0%. Merus NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Qiagen NV pays -- of its earnings as a dividend. Merus NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios QGEN or MRUS?
Qiagen NV quarterly revenues are $501.9M, which are larger than Merus NV quarterly revenues of $11.8M. Qiagen NV's net income of $98.1M is higher than Merus NV's net income of -$99.9M. Notably, Qiagen NV's price-to-earnings ratio is 109.88x while Merus NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Qiagen NV is 4.97x versus 75.06x for Merus NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income QGENQiagen NV4.97x 109.88x $501.9M $98.1M MRUSMerus NV75.06x -- $11.8M -$99.9M
-
Which has Higher Returns QGEN or ORKA?
Oruka Therapeutics has a net margin of 19.54% compared to Qiagen NV's net margin of --. Qiagen NV's return on equity of 2.58% beat Oruka Therapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital QGENQiagen NV61.43% $0.44 $5.4B ORKAOruka Therapeutics-- -$1.46 -- -
What do Analysts Say About QGEN or ORKA?
Qiagen NV has a consensus price target of $51.14, signalling upside risk potential of 14.47%. On the other hand Oruka Therapeutics has an analysts' consensus of $43.17 which suggests that it could grow by 174.6%. Given that Oruka Therapeutics has higher upside potential than Qiagen NV, analysts believe Oruka Therapeutics is more attractive than Qiagen NV.
Company Buy Ratings Hold Ratings Sell Ratings QGENQiagen NV7 7 0 ORKAOruka Therapeutics6 0 0 -
Is QGEN or ORKA More Risky?
Qiagen NV has a beta of 0.366, which suggesting that the stock is 63.358% less volatile than S&P 500. In comparison Oruka Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock QGEN or ORKA?
Qiagen NV has a quarterly dividend of $1.28 per share corresponding to a yield of 0%. Oruka Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Qiagen NV pays -- of its earnings as a dividend. Oruka Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios QGEN or ORKA?
Qiagen NV quarterly revenues are $501.9M, which are larger than Oruka Therapeutics quarterly revenues of --. Qiagen NV's net income of $98.1M is higher than Oruka Therapeutics's net income of -$28.6M. Notably, Qiagen NV's price-to-earnings ratio is 109.88x while Oruka Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Qiagen NV is 4.97x versus -- for Oruka Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income QGENQiagen NV4.97x 109.88x $501.9M $98.1M ORKAOruka Therapeutics-- -- -- -$28.6M
-
Which has Higher Returns QGEN or QURE?
uniQure NV has a net margin of 19.54% compared to Qiagen NV's net margin of -1940.45%. Qiagen NV's return on equity of 2.58% beat uniQure NV's return on equity of -154.29%.
Company Gross Margin Earnings Per Share Invested Capital QGENQiagen NV61.43% $0.44 $5.4B QUREuniQure NV55.36% -$0.91 $106.9M -
What do Analysts Say About QGEN or QURE?
Qiagen NV has a consensus price target of $51.14, signalling upside risk potential of 14.47%. On the other hand uniQure NV has an analysts' consensus of $30.59 which suggests that it could grow by 120.83%. Given that uniQure NV has higher upside potential than Qiagen NV, analysts believe uniQure NV is more attractive than Qiagen NV.
Company Buy Ratings Hold Ratings Sell Ratings QGENQiagen NV7 7 0 QUREuniQure NV8 2 0 -
Is QGEN or QURE More Risky?
Qiagen NV has a beta of 0.366, which suggesting that the stock is 63.358% less volatile than S&P 500. In comparison uniQure NV has a beta of 0.412, suggesting its less volatile than the S&P 500 by 58.797%.
-
Which is a Better Dividend Stock QGEN or QURE?
Qiagen NV has a quarterly dividend of $1.28 per share corresponding to a yield of 0%. uniQure NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Qiagen NV pays -- of its earnings as a dividend. uniQure NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios QGEN or QURE?
Qiagen NV quarterly revenues are $501.9M, which are larger than uniQure NV quarterly revenues of $2.3M. Qiagen NV's net income of $98.1M is higher than uniQure NV's net income of -$44.4M. Notably, Qiagen NV's price-to-earnings ratio is 109.88x while uniQure NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Qiagen NV is 4.97x versus 23.44x for uniQure NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income QGENQiagen NV4.97x 109.88x $501.9M $98.1M QUREuniQure NV23.44x -- $2.3M -$44.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
4 Top Dividend Stocks to Buy Now
If you’re looking for steady income, dividend stocks are a…
Will Uber Stock Recover?
Shares of Uber Technologies (NYSE:UBER) have had a rough few…
Stock Ideas
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 39x
Sell
47
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 114x
Sell
39
Is MSFT Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 36x
Alerts
Buy
87
CEG alert for Jan 11
Constellation Energy [CEG] is up 25.15% over the past day.
Sell
1
MCY alert for Jan 11
Mercury General [MCY] is down 19.87% over the past day.
Buy
84
ATZAF alert for Jan 11
Aritzia [ATZAF] is up 17.63% over the past day.
